Gentamicin Sulfate for Spinal Cord Injuries

Phase-Based Progress Estimates
Spinal Cord Injuries+7 More
Gentamicin Sulfate - Drug
All Sexes
What conditions do you have?

Study Summary

This trial looks at whether a medication can help reduce urinary infections and complications in people with spinal cord injuries, as well as improve their quality of life.

Eligible Conditions
  • Spinal Cord Injuries
  • Spinal Cord Diseases
  • Urinary Tract Infections
  • Neurogenic Urinary Bladder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 6 months

6 months
Neurogenic Urinary Bladder
Change in score of Neurogenic Bowel Dysfunction
Number of urinary tract infections (UTI)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Gentamicin sulfate
1 of 1
Experimental Treatment

25 Total Participants · 1 Treatment Group

Primary Treatment: Gentamicin Sulfate · No Placebo Group · Phase 2 & 3

Gentamicin sulfate
Experimental Group · 1 Intervention: Gentamicin Sulfate · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

University of MichiganLead Sponsor
1,616 Previous Clinical Trials
6,330,844 Total Patients Enrolled
15 Trials studying Spinal Cord Injuries
3,079 Patients Enrolled for Spinal Cord Injuries
Denise Tate, PhDPrincipal Investigator - University of Michigan
University of Michigan
Anne Pelletier-Cameron, MDPrincipal InvestigatorUniversity of Michigan
1 Previous Clinical Trials
24 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to perform daily instillation on self or with help of others and are willing to adhere to the study regiment.
You have a history of SCI or SCD with sustained neurological dysfunction.
You are using clean intermittent catheterization or catheterization through a stoma (i.e.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 4th, 2021

Last Reviewed: October 18th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.